logo
$7.5 million anonymous gift fuels nonprofit support initiative at UAFS

$7.5 million anonymous gift fuels nonprofit support initiative at UAFS

Yahoo12-04-2025

The University of Arkansas–Fort Smith announced a transformational $7.5 million gift on April 2, establishing a comprehensive Center for Nonprofits.
The anonymous donation, one of the largest in UAFS history, was revealed during the public kickoff of the university's $85-million comprehensive campaign, 'Intrepid Ambition.'
'This gift is a profound statement of belief in Fort Smith and the people doing some of the most difficult and most meaningful work in our region,' said Blake Rickman, vice chancellor for university advancement and executive director of the UAFS Foundation. 'The nonprofits of the River Valley are helping families in crisis, walking alongside individuals who feel forgotten and fighting every day for those who have nowhere else to turn. This gift will transform their capacity to do that work, and it's an honor to be a part of it.'
The CNP will be housed within the UAFS Center for Economic Development at the Bakery District downtown and will provide training and community-building opportunities for nonprofit organizations across the River Valley.
'The Center for Nonprofits is a natural extension of the work we do every day at the CED, equipping organizations with practical tools to grow, adapt, and lead,' said Kendall Ross, associate vice chancellor for economic and workforce development and head of the CED. 'This gift allows us to apply that expertise to the nonprofit sector, where the impact is deeply human and profoundly local.'
Ross aims to begin the search for the center's director immediately.
The CNP will support nonprofits in two primary ways: Offering direct training and support to nonprofit staff at the CED and integrating academic expertise through a partnership with the university's Department of Social Work.
Like other UAFS initiatives, such as the Center for Business and Professional Development, the CNP will provide professional development, capacity building, and operational support tailored to nonprofit needs. Training sessions will cover fundraising, financial management, board governance and strategic communications, with opportunities to earn continuing education credits.
The center also will award annual mini-grants to regional nonprofits and provide access to operational resources and technology to enhance service delivery, impact measurement, fundraising and data analysis.
Additionally, the CNP will collaborate with the UAFS Department of Social Work to link academic research with community needs. This partnership will establish an endowed nonprofit faculty position, create applied research initiatives and offer paid student internships, helping to prepare students for careers in the nonprofit sector.
'We recognize that fostering the economic growth of the River Valley is deeply connected with enhancing the social well-being of our community,' said Dr. Shadow Robinson, provost of UAFS. 'This generous gift will allow us to amplify that impact, extending our capacity to serve and strengthen nonprofits throughout the region.'
The CNP will build upon the foundation of River Valley Nonprofits, a local network that emerged in 2020 to support organizations navigating the challenges of the COVID-19 pandemic. This group officially became a 501(c)(3) nonprofit in 2024 and is working closely with UAFS to establish the new center.
'The launch of the UAFS Center for Nonprofits is a defining moment for the nonprofit community in the River Valley,' said Tim Shields, board president and facilitator of River Valley Nonprofits. 'What started as a grassroots effort in 2020 has evolved into a transformative partnership with UAFS. This $7.5 million endowment ensures that nonprofit leaders can access the tools, training, and resources needed to meet future challenges. It's an investment in the people and organizations changing lives in our region and beyond.'
This article originally appeared on Fort Smith Times Record: $7.5M donation fuels nonprofit hub at University of Arkansas–Fort Smith

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

Yahoo

time3 days ago

  • Yahoo

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks - For the TransCon CNP-treated cohort, combination treatment resulted in mean AGV of 8.25 cm/year, with an improvement in mean ACH height Z-score of +0.44 over 26 weeks - The combination of TransCon hGH and TransCon CNP demonstrated accelerated improvement in body proportionality at Week 26, aligning with the increase in linear growth - Safety and tolerability data consistent with those observed for TransCon hGH and TransCon CNP monotherapies; combination treatment was generally well tolerated, with generally mild treatment-emergent adverse events (TEAEs) - Ascendis to host conference call today at 8:00 am ET COPENHAGEN, Denmark, June 09, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 26 interim analysis results from its ongoing COACH Trial, the first clinical trial to evaluate combination treatment with once-weekly investigational TransCon CNP (navepegritide) and once-weekly TransCon hGH (lonapegsomatropin) in children with achondroplasia. Results demonstrated that TransCon hGH boosted treatment benefits of TransCon CNP, resulting in significant growth and proportionality improvements in children with achondroplasia after 26 weeks of combination treatment, with a safety and tolerability profile consistent with those observed for TransCon hGH and TransCon CNP monotherapies. TransCon CNP, which is under priority review as a monotherapy for children with achondroplasia by the U.S. Food & Drug Administration (FDA), is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly, providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle. TransCon hGH is a prodrug of somatropin administered once weekly, providing sustained release of active, unmodified somatropin. TransCon hGH is approved and marketed as SKYTROFA® for the treatment of pediatric growth hormone deficiency and is in development for other indications. 'TransCon CNP as a monotherapy has demonstrated the potential to transform the treatment of achondroplasia, and the COACH Trial at Week 26 demonstrates that TransCon hGH has the potential to boost treatment benefits of TransCon CNP with a safety profile consistent with monotherapies,' said Aimee Shu, M.D., Executive Vice President of Endocrine & Rare Disease Medical Sciences and Chief Medical Officer at Ascendis Pharma. 'These results highlight the unique portfolio of once-weekly TransCon CNP and once-weekly TransCon hGH, with complementary modes of action, to improve the treatment landscape for growth disorders and physical functioning.' COACH Trial DesignThe COACH Trial is an ongoing proof-of-concept prospective Phase 2 open-label trial to investigate the efficacy, safety, and tolerability of combined treatment with once-weekly TransCon CNP at 100 µg/kg/week and once-weekly TransCon hGH at 0.30 mg/kg/week in children with achondroplasia aged 2 to 11 years. The trial included a cohort of TransCon CNP treatment naïve children (N=12, mean age 4.67 years) and a cohort of TransCon CNP-treated children (N=9, mean age 7.89 years) who had received TransCon CNP (100 µg/kg/week) for a mean of 2.56 years in clinical trials. The trial population is representative of children with achondroplasia, except for the observed growth benefit in the TransCon CNP-treated cohort. The interim analysis will be followed by Week 52 data, expected in Q4 2025, and Ascendis plans to initiate a Phase 3 trial in Q4 2025. Highlights of the Interim Topline Week 26 COACH Trial Results For TransCon CNP treatment-naïve children, mean annualized growth velocity (AGV) was 9.14 cm/year, representing an increase from baseline at Week 26 of 4.23 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks. For TransCon CNP-treated children, mean AGV was 8.25 cm/year, representing an increase from baseline at Week 26 of 3.10 cm/year, with an improvement in mean ACH height Z-score of +0.44 over 26 weeks. Mean AGV with TransCon CNP and TransCon hGH combination treatment exceeded the 97th percentile of average-stature children. Children treated with TransCon hGH and TransCon CNP demonstrated accelerated improvement in body proportionality at Week 26, aligning with the increase in linear growth. Bone age advanced in line with chronologic age. Safety and tolerability data were consistent with those observed for TransCon hGH and TransCon CNP monotherapies; combination treatment was generally well tolerated, with generally mild TEAEs. A slide presentation with these data can be found on the Investor Relations & News section of the Ascendis Pharma website: Conference Call and Webcast InformationAscendis Pharma will host a conference call and webcast today at 8:00 am Eastern Time (ET) to discuss these results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at A replay of the webcast will be available on that page shortly after the conclusion of the event for 30 days. About AchondroplasiaAchondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, causing serious muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia vary across different stages of life. Throughout infancy and childhood, observed complications include spinal deformities, enlarged brain ventricles, impaired muscle strength and stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; many of these persist or worsen in adulthood. These medical complications can have detrimental effects on quality of life, physical functioning, and psychosocial function. Individuals with achondroplasia often require multiple surgeries and procedures to alleviate the condition's many complications. About Ascendis Pharma A/SAscendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) TransCon CNP's potential to transform the treatment of achondroplasia, (ii) TransCon hGH's potential to boost treatment benefits of TransCon CNP with a safety profile consistent with monotherapies, (iii) the potential for the combination of TransCon CNP and TransCon hGH to improve the treatment landscape for growth disorders and physical functioning, (iv) the expected timing of Week 52 data from the COACH Trial and Ascendis' plans to initiate a Phase 3 trial in Q4 2025, (v) Ascendis' ability to apply its TransCon technology platform to make a meaningful difference for patients, and (vi) Ascendis' application of its TransCon technologies to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including tariffs and trade policies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, SKYTROFA, and TransCon are trademarks owned by the Ascendis Pharma group. © June 2025 Ascendis Pharma A/S. Investor Contacts: Media Contact: Sarada Weerasinghe Melinda Baker Ascendis Pharma Ascendis Pharma ir@ media@ Patti Bank ICR Healthcare +1 (415) 513-1284 Sign in to access your portfolio

Doppelmayr To Expand Canadian HQ by 185,000 Square Feet
Doppelmayr To Expand Canadian HQ by 185,000 Square Feet

Yahoo

time04-06-2025

  • Yahoo

Doppelmayr To Expand Canadian HQ by 185,000 Square Feet

Late last month, the ski chairlift manufacturer Doppelmayr announced plans to expand its Canadian headquarters in Saint-Jérôme, Québec, over the next 18 months with a new building that includes office, production, and warehousing structure, which covers 185,000 square feet of indoor and outdoor space, will nearly double the size of the preexisting headquarters and is aimed at helping Doppelmayr better serve the North American market, where, according to a press release shared by the company, there is growing demand. 'Our employees do an outstanding job completing all our ropeways on time and to the highest standards," said Gerhard Gassner, the Doppelmayr Group's managing director. "The new building has become essential to continue meeting these expectations."Want to keep up with the best stories and photos in skiing? Subscribe to the new Powder To The People newsletter for weekly updates. 'The current facility has been expanded many times over 45 years, but we are now looking into the future of ropeway business, considering material flow, efficiency, and employee satisfaction,' added Luc Guy, the CEO of Doppelmayr Canada. 'The new facility will be a state-of-the-art manufacturing facility where we will continue to design and produce the highest quality ropeway systems in North America.'The architecture and design of the facility were being finalized as of May 23, when Doppelmayr published the press release. The company anticipated that construction would begin at the end of May, with the goal to have the facility producing ropeways by the last quarter of announcement follows the news of another facility expansion for Doppelmayr. In July 2024, the company shared plans to double the size of its Salt Lake City, Utah, project in Saint-Jérôme was facilitated, in part, by the Canada Economic Development for Quebec Regions (CED), which granted Doppelmayr $3 million in funding for its growing headquarters. 'Businesses are at the heart of community development,' said the Honourable Mélanie Joly, Minister of Industry and Minister responsible for CED. 'We help them invest in equipment and devices that will improve their performance, which is why I am delighted with CED's support for Doppelmayr Canada's project.'A dominant force in the ski resort chairlift marketplace, Doppelmayr's handiwork has featured prominently in several recent and ongoing infrastructure improvements at mountains across the continent. In December 2024, Big Sky Resort, Montana, unveiled the Madison 8, a Doppelmayr product that held the distinction of being the world's longest eight-person chairlift. This summer, Mount St. Louis Moonstone, Ontario, is constructing the Elfriede Huter Xpress, another chairlift from To Expand Canadian HQ by 185,000 Square Feet first appeared on Powder on Jun 3, 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Microblink Unveils First-of-Its-Kind Card-Not-Present Fraud Solution with BlinkCard Integration into Microblink Platform at Money 20/20 Europe
Microblink Unveils First-of-Its-Kind Card-Not-Present Fraud Solution with BlinkCard Integration into Microblink Platform at Money 20/20 Europe

Yahoo

time03-06-2025

  • Yahoo

Microblink Unveils First-of-Its-Kind Card-Not-Present Fraud Solution with BlinkCard Integration into Microblink Platform at Money 20/20 Europe

AMSTERDAM, June 03, 2025--(BUSINESS WIRE)--Microblink, a global leader in identity verification solutions, is raising the bar for fraud prevention and user experience in fintech with a major product breakthrough announced today at Money 20/20 Europe. The company revealed the integration of BlinkCard into the Microblink Platform, making Microblink the only identity verification vendor to offer a comprehensive Card-Not-Present (CNP) fraud solution within an end-to-end identity orchestration framework. This bold expansion cements Microblink's position at the forefront of digital security, arming businesses with an all-in-one, fully automated solution to combat identity and payment fraud in even the most high-risk digital environments. "This is a game-changer," said Hartley Thompson, President and COO at Microblink. "With BlinkCard now embedded directly into the Microblink Platform, our partners can instantly verify not just who their customers are, but also that their payment card is legitimately present. In a world where Card-Not-Present fraud is skyrocketing, we're delivering a solution no one else has: true, seamless identity and payment verification in a single, scalable platform." Merchants choose Microblink's payment card scan with liveness detection functionality to safeguard their Card-Not-Present transactions with card-present evidence. The product also powers an alternative authentication method for financial services providers looking to augment their SMS OTP defenses. The Microblink Platform combines lightning-fast ID capture and global verification with BlinkCard's AI-powered card scanning capabilities, bringing new fraud-fighting muscle to digital payments, card provisioning, and customer authentication. Banks, merchants and payments providers now have access to real-time biometric authentication, document and data validation, and payment fraud checks, all in a frictionless, no-code workflow builder. By combining the capture and screening of credit/debit cards, liveness checks, ID documents and biometrics, Microblink customers can solve use cases, including age verification, CNP fraud reduction and "something you have" authentication. Key benefits of the integrated solution include: Card-Not-Present Fraud Protection – Instantly verify payment card presence alongside identity credentials Frameless, Instant UX – Capture IDs and payment cards in seconds with the industry's fastest, most intuitive UI AI-Driven Fraud Signals – Uncover fraud at the transaction level with biometric checks, injection attack detection, and proprietary machine learning models One Platform. Zero Compromises. – Skip complex integrations and reduce third-party dependencies with a cloud-native, automated platform With this launch, Microblink is redefining what's possible in digital identity—offering an integrated, flexible toolset that reduces fraud, lowers operational overhead, and unlocks better customer experiences. "We're not just solving identity, we're solving trust," Thompson added. "When you can link a real person to a real payment method, in real-time, you build a foundation of security and confidence that moves businesses forward." About Microblink Microblink builds proprietary AI solutions for identity verification and payment fraud, empowering businesses worldwide to improve customers' digital experiences. With more than 12 billion documents processed from over 180 countries, the flagship Microblink Platform is used across industries to onboard more real customers, optimize KYC/AML workflows, and minimize fraud, enabling organizations to make online interactions safer and easier. More at View source version on Contacts Media Contact: Paul WilkeUpright Position Communications on behalf of Microblinkpaul@ +1-415-881-7995

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store